Verve Therapeutics Inc (VERV) — Defensive Interval Ratio
Verve Therapeutics Inc (VERV) has a Defensive Interval Ratio of 2822 days as of March 2025. Defensive assets of $401.92 Million (cash $-, short-term investments $400.52 Million, receivables $1.40 Million) cover 2822 days of daily cash needs of $142.41K/day. See VERV working capital efficiency to evaluate short-term liquidity relative to the company's equity base.
Defensive Interval Ratio
Defensive Assets
Daily Cash Need
Current Liabilities
Verve Therapeutics Inc Defensive Interval Ratio (2019–2024)
This chart shows how Verve Therapeutics Inc's Defensive Interval Ratio has evolved across 6 annual periods from 2019 to 2024. As of March 2025, the ratio stands at 2822 days, meaning defensive assets of $401.92 Million can fund 2822 days of operations without new revenue. See Verve Therapeutics Inc (VERV) net asset quality to measure how much of total assets are equity-financed.
Annual Defensive Interval Ratio for Verve Therapeutics Inc (2019–2024)
The table below presents the year-by-year Defensive Interval Ratio for Verve Therapeutics Inc from 2019 to 2024, covering 6 annual filings. Each row shows defensive assets, daily cash need, the DIR in days, and the change in days compared to the prior year. For live market cap and the full company financial profile, see Verve Therapeutics Inc (VERV) market capitalisation.
| Year | DIR (days) | Defensive Assets (USD) | Daily Cash Need | Cash | ST Investments | Change (days) |
|---|---|---|---|---|---|---|
| 2024 | 3020 days | $354.98 Million | $117.56K/day | $- | $351.72 Million | ▼ -1159 days |
| 2023 | 4179 days | $423.67 Million | $101.39K/day | $- | $417.77 Million | ▼ -402 days |
| 2022 | 4580 days | $440.41 Million | $96.15K/day | $- | $439.40 Million | ▼ -372 days |
| 2021 | 4952 days | $298.81 Million | $60.34K/day | $- | $296.11 Million | ▲ +1803 days |
| 2020 | 3149 days | $63.12 Million | $20.04K/day | $- | $63.12 Million | ▲ +1527 days |
| 2019 | 1623 days | $15.80 Million | $9.73K/day | $- | $15.80 Million | — |